IP Library Granted Patent US 11,278,638
Granted Patent B2
US 11,278,638 · App. 16/417,256 · Granted Mar 22, 2022

Wound dressing materials

Inventor: Lorraine Nisbet (Skipton, GB)
Assignee: Systagenix Wound Management, Limited
A61L15/44A61F13/00063A61F13/0206A61L15/225A61L15/26A61L15/32A61L15/58A61L15/64A61L2300/214A61L2300/216A61L2300/40A61L2300/428A61L2300/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,278,638
App. No.
16/417,256
Granted
Mar 22, 2022
Kind
B2
Abstract

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials.

Claims (25)

1. A method of making a wound dressing, the method comprising the steps of:

forming an aqueous dispersion, the aqueous dispersion comprising a bioabsorbable carrier material, N-acetyl cysteine or a salt thereof, a stabilized ascorbate, and an aqueous solvent, wherein a weight ratio of N-acetyl cysteine or a salt thereof to the stabilized ascorbate is from about 1:4 to about 4:1; and

freeze-drying or solvent-drying the aqueous dispersion to produce an active layer; wherein

the wound dressing comprises the active layer;

the active layer comprises a wound-facing side, the bioabsorbable carrier material, the N-acetyl cysteine or a salt thereof, and the stabilized ascorbate, where a weight ratio of N-acetyl cysteine or a salt thereof to the stabilized ascorbate is from about 1:4 to about 4:1 in the active layer; and

the stabilized ascorbate comprises a member selected from the group consisting of ascorbate 2-phosphate or polyphosphate compounds, trisodium L-ascorbyl-2-monophosphate, 2-phospho-L-ascorbic acid trisodium salt, magnesium ascorbyl phosphate (MAP), L-ascorbic acid mono(dihydrogen phosphate) magnesium salt, magnesium L-ascorbic acid-2-phosphate, trisodium L-ascorbyl-2-polyphosphate, and a combination of any two or more thereof.

2. The method of claim 1 , wherein the bioabsorbable carrier material is adapted to provide sustainable release of N-acetyl cysteine or a salt thereof and the stabilized ascorbate.

3. The method of claim 1 , wherein the active layer is in the form of a sponge.

4. The method of claim 1 , wherein the carrier material comprises oxidized cellulose.

5. The method of claim 1 , wherein the carrier material comprises collagen, chitosan, or both.

6. The method of claim 1 , wherein the carrier material comprises oxidized cellulose and one or both of collagen and chitosan.

7. The method of claim 1 , wherein the carrier material comprises oxidized regenerated cellulose.

8. The method of claim 1 , wherein the carrier material comprises oxidized regenerated cellulose and one or both of collagen and chitosan.

9. The method of claim 1 , wherein the stabilized ascorbate comprises ascorbate-2-tripho sphate.

10. The method of claim 1 , wherein the active layer comprises from about 1 wt.% to about 10 wt.% of the N-acetyl cysteine or a salt thereof, and from about 1 wt.% to about 10 wt.% of the stabilized ascorbate.

11. The method of claim 1 , wherein the aqueous dispersion comprises a solids concentration from about 0.5 wt.% to about 3 wt.%.

12. The method of claim 1 , wherein the aqueous dispersion comprises about 0.0002 wt.% to about 1 wt.% of the N-acetyl cysteine or a salt thereof.

13. The method of claim 1 , wherein the aqueous dispersion comprises about 0.03 wt.% to about 0.4 wt.% of the N-acetyl cysteine or a salt thereof.

14. The method of claim 1 , wherein the aqueous dispersion comprises about 0.05 wt.% to about 0.3 wt.% of the N-acetyl cysteine or a salt thereof.

15. The method of claim 1 , wherein the aqueous dispersion comprises about 0.0002 wt.% to about 1 wt.% of the stabilized ascorbate.

16. The method of claim 1 , wherein the aqueous dispersion comprises about 0.03 wt.% to about 0.4 wt.% of the stabilized ascorbate.

17. The method of claim 1 , wherein the aqueous dispersion comprises about 0.05 wt.% to about 0.3 wt.% of the stabilized ascorbate.

18. The method of claim 1 , the method further comprising treating the aqueous dispersion with a cross-linking agent.

19. The method of claim 18 , wherein the cross-linking agent comprises a carbodiimide, epichlorhydrin, hexamethylene diisocyanate, or glutaraldehyde.

20. The method of claim 1 , the method further comprising treating the active layer with a cross-linking agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2020
From: KCI USA, INC.
To: SYSTAGENIX WOUND MANAGEMENT, LIMITED
Reel/Frame 052496/0695 →
Cited By (1)
US 12,415,014